SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-22-009689
Filing Date
2022-06-02
Accepted
2022-06-02 17:30:25
Documents
7
Period of Report
2022-06-02

Document Format Files

Seq Description Document Type Size
1 6-K tmb-20220602x6k.htm 6-K 24136
2 EX-99.1 tmb-20220602xex99d1.htm EX-99.1 7545
3 EX-99.2 tmb-20220602xex99d2.htm EX-99.2 36367
4 EX-99.3 tmb-20220602xex99d3.htm EX-99.3 7703
5 GRAPHIC tmb-20220602xex99d1001.jpg GRAPHIC 7971
6 GRAPHIC tmb-20220602xex99d3g001.jpg GRAPHIC 206306
7 GRAPHIC tmb-20220602xex99d3g002.jpg GRAPHIC 107667
  Complete submission text file 0001558370-22-009689.txt   520558
Mailing Address YALELAAN 60 UTRECHT P7 3584 CM
Business Address YALELAAN 60 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40241 | Film No.: 22992120
SIC: 2834 Pharmaceutical Preparations